Showing 1,041 - 1,060 results of 226,405 for search '(( a ((a decrease) OR (linear decrease)) ) OR ( a ((greater decrease) OR (larger decrease)) ))', query time: 1.54s Refine Results
  1. 1041
  2. 1042
  3. 1043
  4. 1044
  5. 1045

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  6. 1046

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  7. 1047

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  8. 1048

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  9. 1049

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  10. 1050
  11. 1051
  12. 1052
  13. 1053

    Flies decrease the level of aggression as the availability of food resource increases. by Rod S. Lim (622045)

    Published 2014
    “…(c) Male-male courtship normalized by locomotion shows no increase or decrease (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105626#pone.0105626.s012" target="_blank">Table S4</a> for statistics). …”
  14. 1054

    HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial by Anita Y.M. Kwan (11868016)

    Published 2022
    “…</p> <p><b>Conclusions:</b> Dulaglutide 1.5 mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.…”
  15. 1055
  16. 1056
  17. 1057
  18. 1058
  19. 1059
  20. 1060

    Supplementary Material for: Larger degree of renal function decline in CKD is a favorable factor for the attenuation of eGFR slope worsening by SGLT2 inhibitors: a retrospective ob... by Miyaoka Y. (18280342)

    Published 2024
    “…Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) have beneficial effects on the renal function of chronic kidney disease (CKD) patients, although the types of patients suitable for this treatment remain unclear. Methods: A retrospective observational study was conducted on CKD patients who were treated with SGLT2I at our department from 2020 to 2023. …”